Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: MMP2

Gene summary for MMP2

Gene summary.

Gene information	Species	Human
	Gene symbol	MMP2
	Gene ID	4313
	Gene name	matrix metallopeptidase 2
	Gene Alias	CLG4
	Cytomap	16q12.2
	Gene Type	protein-coding
	GO ID	GO:0000003
	UniProtAcc	P08253

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
4313	MMP2	AEH-subject1	Human	Endometrium	AEH	5.07e-19	-6.37e-01	-0.3059
4313	MMP2	AEH-subject2	Human	Endometrium	AEH	1.85e-24	-7.09e-01	-0.2525
4313	MMP2	AEH-subject3	Human	Endometrium	AEH	9.84e-33	-7.89e-01	-0.2576
4313	MMP2	AEH-subject4	Human	Endometrium	AEH	2.50e-13	-6.27e-01	-0.2657
4313	MMP2	AEH-subject5	Human	Endometrium	AEH	2.36e-40	-8.18e-01	-0.2953
4313	MMP2	EEC-subject1	Human	Endometrium	EEC	1.99e-26	-7.44e-01	-0.2682
4313	MMP2	EEC-subject2	Human	Endometrium	EEC	1.20e-41	-8.14e-01	-0.2607
4313	MMP2	EEC-subject3	Human	Endometrium	EEC	3.14e-31	-6.47e-01	-0.2525
4313	MMP2	EEC-subject4	Human	Endometrium	EEC	7.49e-29	-7.61e-01	-0.2571
4313	MMP2	EEC-subject5	Human	Endometrium	EEC	6.74e-33	-7.70e-01	-0.249
4313	MMP2	GSM5276935	Human	Endometrium	EEC	3.89e-30	-7.50e-01	-0.123
4313	MMP2	GSM6177620_NYU_UCEC1_lib1_lib1	Human	Endometrium	EEC	1.79e-24	-7.22e-01	-0.1869
4313	MMP2	GSM6177620_NYU_UCEC1_lib2_lib2	Human	Endometrium	EEC	1.49e-24	-6.90e-01	-0.1875
4313	MMP2	GSM6177620_NYU_UCEC1_lib3_lib3	Human	Endometrium	EEC	1.99e-28	-6.57e-01	-0.1883
4313	MMP2	GSM6177621_NYU_UCEC2_lib1_lib1	Human	Endometrium	EEC	1.71e-39	-7.78e-01	-0.1934
4313	MMP2	GSM6177622_NYU_UCEC3_lib1_lib1	Human	Endometrium	EEC	1.19e-42	-8.16e-01	-0.1917
4313	MMP2	GSM6177622_NYU_UCEC3_lib2_lib2	Human	Endometrium	EEC	6.57e-48	-8.29e-01	-0.1916
4313	MMP2	P2T-E	Human	Esophagus	ESCC	1.02e-09	3.20e-01	0.1177
4313	MMP2	P4T-E	Human	Esophagus	ESCC	1.56e-04	1.39e+00	0.1323
4313	MMP2	P9T-E	Human	Esophagus	ESCC	1.22e-07	1.70e+00	0.1131

Page: 1 2 3 4 5

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00229049	Cervix	CC	respiratory electron transport chain	42/2311	114/18723	1.67e-11	4.77e-09	42
GO:00453339	Cervix	CC	cellular respiration	66/2311	230/18723	2.07e-11	5.39e-09	66
GO:00725949	Cervix	CC	establishment of protein localization to organelle	99/2311	422/18723	1.23e-10	2.11e-08	99
GO:00229009	Cervix	CC	electron transport chain	53/2311	175/18723	2.23e-10	3.43e-08	53
GO:00060919	Cervix	CC	generation of precursor metabolites and energy	105/2311	490/18723	7.40e-09	6.61e-07	105
GO:00026837	Cervix	CC	negative regulation of immune system process	94/2311	434/18723	2.63e-08	1.87e-06	94
GO:00603267	Cervix	CC	cell chemotaxis	73/2311	310/18723	2.82e-08	1.96e-06	73
GO:00159809	Cervix	CC	energy derivation by oxidation of organic compounds	74/2311	318/18723	3.83e-08	2.53e-06	74
GO:00975298	Cervix	CC	myeloid leukocyte migration	56/2311	220/18723	7.21e-08	4.15e-06	56
GO:00305957	Cervix	CC	leukocyte chemotaxis	57/2311	230/18723	1.48e-07	7.07e-06	57
GO:00068399	Cervix	CC	mitochondrial transport	60/2311	254/18723	4.21e-07	1.67e-05	60
GO:00509007	Cervix	CC	leukocyte migration	78/2311	369/18723	1.09e-06	3.80e-05	78
GO:00614588	Cervix	CC	reproductive system development	87/2311	427/18723	1.37e-06	4.55e-05	87
GO:00486088	Cervix	CC	reproductive structure development	86/2311	424/18723	1.90e-06	5.97e-05	86
GO:000660510	Cervix	CC	protein targeting	68/2311	314/18723	2.17e-06	6.55e-05	68
GO:00026857	Cervix	CC	regulation of leukocyte migration	50/2311	210/18723	2.95e-06	8.31e-05	50
GO:00026888	Cervix	CC	regulation of leukocyte chemotaxis	34/2311	122/18723	3.00e-06	8.38e-05	34
GO:00509203	Cervix	CC	regulation of chemotaxis	51/2311	223/18723	8.03e-06	1.86e-04	51
GO:00705859	Cervix	CC	protein localization to mitochondrion	33/2311	125/18723	1.46e-05	2.90e-04	33
GO:00512713	Cervix	CC	negative regulation of cellular component movement	73/2311	367/18723	2.22e-05	3.95e-04	73

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0541525	Endometrium	AEH	Diabetic cardiomyopathy	86/1197	203/8465	2.62e-23	1.22e-21	8.90e-22	86
hsa0541826	Endometrium	AEH	Fluid shear stress and atherosclerosis	43/1197	139/8465	2.47e-07	3.49e-06	2.55e-06	43
hsa0467026	Endometrium	AEH	Leukocyte transendothelial migration	37/1197	114/8465	4.51e-07	6.11e-06	4.47e-06	37
hsa0520518	Endometrium	AEH	Proteoglycans in cancer	53/1197	205/8465	5.43e-06	6.53e-05	4.78e-05	53
hsa049337	Endometrium	AEH	AGE-RAGE signaling pathway in diabetic complications	28/1197	100/8465	2.11e-04	1.80e-03	1.32e-03	28
hsa0491525	Endometrium	AEH	Estrogen signaling pathway	35/1197	138/8465	3.10e-04	2.40e-03	1.75e-03	35
hsa05415111	Endometrium	AEH	Diabetic cardiomyopathy	86/1197	203/8465	2.62e-23	1.22e-21	8.90e-22	86
hsa05418112	Endometrium	AEH	Fluid shear stress and atherosclerosis	43/1197	139/8465	2.47e-07	3.49e-06	2.55e-06	43
hsa04670111	Endometrium	AEH	Leukocyte transendothelial migration	37/1197	114/8465	4.51e-07	6.11e-06	4.47e-06	37
hsa0520519	Endometrium	AEH	Proteoglycans in cancer	53/1197	205/8465	5.43e-06	6.53e-05	4.78e-05	53
hsa0493314	Endometrium	AEH	AGE-RAGE signaling pathway in diabetic complications	28/1197	100/8465	2.11e-04	1.80e-03	1.32e-03	28
hsa04915111	Endometrium	AEH	Estrogen signaling pathway	35/1197	138/8465	3.10e-04	2.40e-03	1.75e-03	35
hsa0541526	Endometrium	EEC	Diabetic cardiomyopathy	86/1237	203/8465	2.59e-22	9.46e-21	7.05e-21	86
hsa0541827	Endometrium	EEC	Fluid shear stress and atherosclerosis	45/1237	139/8465	7.76e-08	1.22e-06	9.07e-07	45
hsa0467027	Endometrium	EEC	Leukocyte transendothelial migration	36/1237	114/8465	2.97e-06	3.91e-05	2.91e-05	36
hsa0520524	Endometrium	EEC	Proteoglycans in cancer	52/1237	205/8465	3.01e-05	3.19e-04	2.38e-04	52
hsa0493321	Endometrium	EEC	AGE-RAGE signaling pathway in diabetic complications	28/1237	100/8465	3.68e-04	3.03e-03	2.26e-03	28
hsa0491526	Endometrium	EEC	Estrogen signaling pathway	34/1237	138/8465	1.19e-03	8.02e-03	5.98e-03	34
hsa0541535	Endometrium	EEC	Diabetic cardiomyopathy	86/1237	203/8465	2.59e-22	9.46e-21	7.05e-21	86
hsa0541836	Endometrium	EEC	Fluid shear stress and atherosclerosis	45/1237	139/8465	7.76e-08	1.22e-06	9.07e-07	45

Page: 1 2 3 4 5

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

MMP2

SNV

Missense_Mutation

c.1116N>C

p.Lys372Asn

p.K372N

P08253

protein_coding

deleterious(0.02)

probably_damaging(0.994)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MMP2

SNV

Missense_Mutation

rs759302357

c.682G>A

p.Ala228Thr

p.A228T

P08253

protein_coding

deleterious(0)

probably_damaging(0.935)

TCGA-AR-A0U2-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Hormone Therapy

tamoxiphen

MMP2

SNV

Missense_Mutation

novel

c.1512N>T

p.Met504Ile

p.M504I

P08253

protein_coding

tolerated(0.2)

benign(0)

TCGA-EW-A6S9-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

MMP2

SNV

Missense_Mutation

c.970G>A

p.Asp324Asn

p.D324N

P08253

protein_coding

deleterious(0.01)

benign(0.074)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

MMP2

SNV

Missense_Mutation

rs772094112

c.275N>G

p.Asn92Ser

p.N92S

P08253

protein_coding

tolerated(0.73)

benign(0)

TCGA-C5-A3HL-01

Cervix

cervical & endocervical cancer

Female

>=65

I/II

Unknown

MMP2

SNV

Missense_Mutation

c.1295G>C

p.Arg432Pro

p.R432P

P08253

protein_coding

tolerated(0.35)

probably_damaging(0.999)

TCGA-EK-A2PI-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Unknown

MMP2

SNV

Missense_Mutation

c.1116N>C

p.Lys372Asn

p.K372N

P08253

protein_coding

deleterious(0.02)

probably_damaging(0.994)

TCGA-IR-A3LA-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

MMP2

SNV

Missense_Mutation

c.1345C>G

p.Pro449Ala

p.P449A

P08253

protein_coding

deleterious(0.01)

benign(0.001)

TCGA-IR-A3LH-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

MMP2

SNV

Missense_Mutation

c.1818C>G

p.Ile606Met

p.I606M

P08253

protein_coding

tolerated(0.14)

probably_damaging(0.999)

TCGA-Q1-A73O-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

MMP2

SNV

Missense_Mutation

c.1896C>G

p.Phe632Leu

p.F632L

P08253

protein_coding

tolerated(0.24)

probably_damaging(0.966)

TCGA-Q1-A73O-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

Page: 1 2 3 4 5 6 7 8 9

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
4313	MMP2	NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE	inhibitor	178101832
4313	MMP2	NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE		SERMS		15576828
4313	MMP2	NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE		MARIMASTAT	MARIMASTAT
4313	MMP2	NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE		PMID29130358-Compound-SB-3CT
4313	MMP2	NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE		BMS-275291	REBIMASTAT	15041713
4313	MMP2	NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE		SIMVASTATIN	SIMVASTATIN	16436088
4313	MMP2	NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE		POLYPHENOL		15324350
4313	MMP2	NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE		HEPARAN SULFATE		12972284
4313	MMP2	NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE		PRAVASTATIN	PRAVASTATIN	15842807
4313	MMP2	NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE		RO-26-2853

Page: 1 2 3 4 5 6